Clinical Trials Directory

Trials / Completed

CompletedNCT02147210

Chronic Transplant Glomerulopathy and Regulation of Expression of Ephrin B1

Status
Completed
Phase
Study type
Observational
Enrollment
60 (estimated)
Sponsor
University Hospital, Toulouse · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

The principal purpose is the study of the regulation of the expression of ephrin-B1 by immunofluorescence in kidney biopsies of patients with Chronic transplant glomerulopathy (CTG) compared to biopsies prior to the CTG, in same patients. Level of fluorescence in CTG biopsy will be the experimental reference value.

Detailed description

Chronic transplant glomerulopathy (CTG) is a specific lesion of kidney transplantation and a poor prognostic factor affecting transplant survival. Diagnosis remains only microscopic and lesions are irreversible. Recent studies prove that there is a strong correlation between CTG and antibody mediated rejection (AMR) with a possible link with chronic aggression of the endothelial cell. However, for unknown reason, all AMR does not lead to a CTG. Our recent data on mice demonstrated that ephrin-B1 is expressed in the glomerular endothelial cells and knockout mice for the gene encoding ephrin-B1 develop progressively ultrastructural glomerular lesions close to modifications observed in CTG, as well as proteinuria and chronic renal failure, suggesting that ephrin B1 could participate to CTG. Moreover, in a preliminary study on human kidney transplant biopsy we observed decrease in ephrin-B1 immunofluorescence on glomerulus when CTG, even in low grade. These data, and ultrastructural modifications in Knock Out (KO) mice suggest that early regulation of kidney expression of ephrin-B1 in the glomerulus may occur during the process leading to the CTG as antibody-mediated kidney rejection (AMR). The purpose of the study is to determinate if ephrin-B1 expression is modified in CTG.

Conditions

Interventions

TypeNameDescription
OTHERbiological analysis

Timeline

Start date
2013-09-01
Primary completion
2016-12-01
Completion
2016-12-01
First posted
2014-05-26
Last updated
2017-03-07

Locations

1 site across 1 country: France

Source: ClinicalTrials.gov record NCT02147210. Inclusion in this directory is not an endorsement.